Transthyretin Amyloidosis (ATTR) - Epidemiology Forecast to 2027

October 2018 | | ID: T55463808E5EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Transthyretin Amyloidosis (ATTR) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Transthyretin Amyloidosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

GEOGRAPHY COVERED

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2015-2027

Transthyretin Amyloidosis (ATTR) Epidemiology

The Transthyretin Amyloidosis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Transthyretin Amyloidosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Transthyretin Amyloidosis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, type-specific diagnosed prevalent cases, treatable cases and Surgery Cases of ATTR related Carpal Tunnel Syndrome) scenario of Transthyretin Amyloidosis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total diagnosed prevalent population of Transthyretin Amyloidosis (ATTR) was found to be 19,160 in the year 2016 in 7MM.

REPORT SCOPE

• The report covers detailed overview of Transthyretin Amyloidosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Transthyretin Amyloidosis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by type i.e., Hereditary [FAP (FAP Stage 0, I,II,III) & FAC] and non-hereditary cases of ATTR in 7MM

KEY STRENGTHS

• 10 Year Forecast of Transthyretin Amyloidosis epidemiology
• 7MM Coverage
• Total Prevalent Cases of ATTR
• Prevalent Cases according to segmentation: Type prevalence i.e., Hereditary & Non-hereditary ATTR
• Diagnosed cases of ATTR

KEY ASSESSMENTS

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. DISEASE BACKGROUND AND OVERVIEW: TRANSTHYRETIN-RELATED AMYLOIDOSIS (ATTR)

2.1. Introduction
2.2. Clinical aspects of ATTR
2.3. Types of Transthyretin Amyloidosis (ATTR)
2.4. Disease Causes
2.5. ATTR-Symptoms
2.6. Pathogenesis
2.7. ATTR Diagnosis
  2.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
  2.7.2. Red flag symptoms associated with hATTR Amyloidosis
  2.7.3. Confirmation of hATTR Amyloidosis diagnosis
  2.7.4. Tools for evaluating TTR-FAP progression
  2.7.5. Tests for detecting Carpal tunnel syndrome

3. EPIDEMIOLOGY AND PATIENT POPULATION

3.1. Key Findings
3.2. Population and Forecast Parameters
3.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
3.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific

4. COUNTRY WISE-EPIDEMIOLOGY OF TRANSTHYRETIN AMYLOIDOSIS (ATTR)

4.1. United States
  4.1.1. Diagnosed Prevalent Population of ATTR in the United States
  4.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
  4.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
4.2. Germany
  4.2.1. Diagnosed Prevalent Population of ATTR in Germany
  4.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
  4.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
4.3. France
  4.3.1. Diagnosed Prevalent Population of ATTR in France
  4.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
  4.3.3. Treatable cases of Transthyretin Amyloidosis in France
4.4. Italy
  4.4.1. Diagnosed Prevalent Population of ATTR in Italy
  4.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
  4.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
4.5. Spain
  4.5.1. Diagnosed Prevalent Population of ATTR in Spain
  4.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
  4.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
4.6. United Kingdom
  4.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
  4.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
  4.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
4.7. Japan
  4.7.1. Diagnosed Prevalent Population of ATTR in Japan
  4.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
  4.7.3. Treatable cases of Transthyretin Amyloidosis in Japan

5. DIAGNOSED SURGERY CASES OF ATTR RELATED CARPAL TUNNEL SYNDROME

5.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
5.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
5.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
5.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
5.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
5.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
5.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome

6. APPENDIX

6.1. Report Methodology

7. DELVEINSIGHT CAPABILITIES

8. DISCLAIMER

9. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2027)
Table 2: Type Specific-Prevalent Population of ATTR in the 7MM (2015-2027)
Table 3: Diagnosed Prevalent Population of ATTR in the United States (2015-2027)
Table 4: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2027)
Table 5: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2027)
Table 6: Diagnosed Prevalent Population of ATTR in Germany (2015-2027)
Table 7: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2027)
Table 8: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2027)
Table 9: Diagnosed Prevalent Population of ATTR in France (2015-2027)
Table 10: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2027)
Table 11: Treatable cases of Transthyretin Amyloidosis in France (2015-2027)
Table 12: Diagnosed Prevalent Population of ATTR in Italy (2015-2027)
Table 13: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2027)
Table 14: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2027)
Table 15: Diagnosed Prevalent Population of ATTR in Spain (2015-2027)
Table 16: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2027)
Table 17: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2027)
Table 18: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2027)
Table 19: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2027)
Table 20: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2027)
Table 21: Diagnosed Prevalent Population of ATTR in Japan (2015-2027)
Table 22: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2027)
Table 23: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2027)
Table 24: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2027)
Table 25: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2027)
Table 26: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2027)
Table 27: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2027)
Table 28: ATTR related Carpal Tunnel Syndrome Surgery Cases in the Italy (2015-2027)
Table 29: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2027)
Table 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2027)
Table 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2027)

List Of Figures

LIST OF FIGURES

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2027)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2027)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2027)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2027)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2027)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2027)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2027)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2027)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2027)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2027)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2027)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2027)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2027)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2027)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2027)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2027)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2027)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2027)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2027)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2027)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2027)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2027)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2027)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2027)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2027)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2027)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2027)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2027)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2027)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2027)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2027)